7 results on '"Skvortsov, Dmitry A."'
Search Results
2. Synthesis of Prostate-Specific Membrane Antigen-Targeted Bimodal Conjugates of Cytotoxic Agents and Antiandrogens and Their Comparative Assessment with Monoconjugates.
- Author
-
Zyk, Nikolai Y., Garanina, Anastasiia S., Plotnikova, Ekaterina A., Ber, Anton P., Nimenko, Ekaterina A., Dashkova, Natalia S., Uspenskaia, Anastasiia A., Shafikov, Radik R., Skvortsov, Dmitry A., Petrov, Stanislav A., Pankratov, Andrey A., Zyk, Nikolai V., Majouga, Alexander G., Beloglazkina, Elena K., and Machulkin, Aleksei E.
- Subjects
ANTIANDROGENS ,PROSTATE cancer ,ANDROGEN receptors ,CHEMICAL synthesis ,CANCER patients ,TUMOR growth - Abstract
Prostate cancer is the second most common cancer among men. We designed and synthesized new ligands targeting prostate-specific membrane antigen and suitable for bimodal conjugates with diagnostic and therapeutic agents. In vitro studies of the affinity of the synthesized compounds to the protein target have been carried out. Based on these ligands, a series of bimodal conjugates with a combination of different mitosis inhibitors and antiandrogenic drugs were synthesized. The cytotoxicity of the compounds obtained in vitro was investigated on three different cell lines. The efficacy of the two obtained conjugates was evaluated in vivo in xenograft models of prostate cancer. These compounds have been shown to be highly effective in inhibiting the growth of PSMA-expressing tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
- Author
-
Machulkin, Alexey E., Skvortsov, Dmitry A., Ivanenkov, Yan A., Ber, Anton P., Kavalchuk, Mikhail V., Aladinskaya, Anastasia V., Uspenskaya, Anastasia A., Shafikov, Radik R., Plotnikova, Ekaterina A., Yakubovskaya, Raisa I., Nimenko, Ekaterina A., Zyk, Nikolay U., Beloglazkina, Elena K., Zyk, Nikolay V., Koteliansky, Victor E, and Majouga, Alexander G.
- Subjects
- *
PACLITAXEL , *BIOSYNTHESIS - Abstract
Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional chemotherapy has wide variety of disadvantages such as high systemic toxicity and low selectivity. Targeted drug delivery is a promising approach to decrease side effects of therapy. Prostate specific membrane antigen (PSMA) is overexpressed in prostate cancer cells while low level of expression is observed in normal cells. In this study we describe the development of Glu-urea-Lys based PSMA-targeting conjugates with paclitaxel. A series of new PSMA targeting conjugates with paclitaxel was designed and synthesized. The cytotoxicity of conjugates was evaluated against prostate (LNCaP, 22Rv1 and PC-3) and non-prostate (Hek293T, VA13, A549 and MCF-7) cell lines. The most promising conjugate 21 was examined in vivo using 22Rv1 xenograft mice model. It demonstrated good efficiency comparable with paclitaxel, while reduced toxicity. 3D molecular docking study was also performed to understand underlying mechanism of binding and further optimization of the linker substructure and conjugates structure for improving the target affinity. These conjugates may be useful for further design of novel PSMA targeting delivery systems for PC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Influence of the dipeptide linker configuration on the activity of PSMA ligands.
- Author
-
Uspenskaya, Anastasiya A., Machulkin, Alexey E., Nimenko, Ekaterina A., Shafikov, Radik R., Petrov, Stanislav A., Skvortsov, Dmitry A., Beloglazkina, Elena K., and Majouga, Alexander G.
- Subjects
- *
DIPEPTIDES , *SOLID-phase synthesis , *LIGANDS (Chemistry) , *CHIRAL centers , *PROSTATE-specific membrane antigen , *PHENYLALANINE , *PEPTIDE synthesis - Abstract
Selective ligands of an urea-based prostate specific membrane antigen with a phenylalanine/tyrosine-based dipeptide linker and with a mingled chiral centers configuration and/or substituted aromatic fragments were prepared in seven steps by liquid- and in six steps by solid-phase synthesis. In vitro test for inhibiting the cleavage of N -acetylaspartylglutamate revealed the optimum linker containing l -phenylalanine in the structure on the N-terminus of a dipeptide chain. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
- Author
-
Ivanenkov, Yan A., Machulkin, Alexey E., Garanina, Anastasia S., Skvortsov, Dmitry A., Uspenskaya, Anastasia A., Deyneka, Ekaterina V., Trofimenko, Alexander V., Beloglazkina, Elena K., Zyk, Nikolay V., Koteliansky, Victor E, Bezrukov, Dmitry S., Aladinskaya, Anastasia V., Vorobyeva, Nataliya S., Puchinina, Maria M., Riabykh, Grigory K., Sofronova, Alina A., Malyshev, Alexander S., and Majouga, Alexander G.
- Subjects
- *
BIOSYNTHESIS , *DRUG side effects , *PROSTATE-specific membrane antigen , *PROTEIN drugs , *MOLECULAR docking , *DOXORUBICIN - Abstract
Graphical abstract Abstract Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an attractive protein trap for drug targeting. At the present time, several drugs and molecular diagnostic tools conjugated with selective PSMA ligands are actively evaluated in different preclinical and clinical trials. In the current work, we discuss design, synthesis and a preliminary biological evaluation of PSMA-specific small-molecule carrier equipped by Doxorubicin (Dox). We have introduced an unstable azo-linker between Dox and the carrier hence the designed compound does release the active substance inside cancer cells thereby providing a relatively high Dox concentration in nuclei and a relevant cytotoxic effect. In contrast, we have also synthesized a similar conjugate with a stable amide linker and it did not release the drug at all. This compound was predominantly accumulated in cytoplasm and did not cause cell death. Preliminary in vivo evaluation has showed good efficiency for the degradable conjugate against PC3-PIP(PSMA+)-containing xenograft mine. Thus, we have demonstrated that the conjugate can be used as a template to design novel analogues with improved targeting, anticancer activity and lower rate of potential side effects. 3D molecular docking study has also been performed to elucidate the underlying mechanism of binding and to further optimization of the linker area for improving the target affinity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Synthesis and initial in vitro evaluation of PSMA-targeting ligands with a modified aromatic moiety at the lysine ε-nitrogen atom.
- Author
-
Zyk, Nikolai Y., Ber, Anton P., Nimenko, Ekaterina A., Shafikov, Radik R., Evteev, Sergei A., Petrov, Stanislav A., Uspenskaya, Anastasia A., Dashkova, Natalia S., Ivanenkov, Yan A., Skvortsov, Dmitry A., Beloglazkina, Elena K., Majouga, Alexander G., and Machulkin, Aleksei E.
- Subjects
- *
LYSINE , *MOIETIES (Chemistry) - Abstract
[Display omitted] We report an improved series of ligands targeting prostate specific membrane antigen (PSMA). The new compounds were designed by the introduction of changes in the structure of the aromatic fragment at ε-nitrogen atom of lysine that resulted in improved biological parameters. Some of them demonstrated high selectivity and nanomolar IC 50 values. We synthesized and tested two conjugates with a fluorescent label Sulfo-Cy5 as an example of the use of the obtained PSMA inhibitors as a basis for the creation of diagnostic preparations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
- Author
-
Machulkin, Aleksei E., Uspenskaya, Anastasia A., Zyk, Nikolay Y., Nimenko, Ekaterina A., Ber, Anton P., Petrov, Stanislav A., Shafikov, Radik R., Skvortsov, Dmitry A., Smirnova, Galina B., Borisova, Yulia A., Pokrovsky, Vadim S., Kolmogorov, Vasilii S., Vaneev, Alexander N., Ivanenkov, Yan A., Khudyakov, Alexander D., Kovalev, Sergei V., Erofeev, Alexander S., Gorelkin, Petr V., Beloglazkina, Elena K., and Zyk, Nikolay V.
- Subjects
- *
DOCETAXEL , *ANTINEOPLASTIC agents , *THERAPEUTICS , *TUMOR growth , *ETIOLOGY of cancer , *PROSTATE cancer - Abstract
Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of the leading causes of cancer death. The development of approaches to the treatment of this oncological disease is an ongoing process. In this work, we have carried out the selection of ligands for the creation of conjugates based on the drug docetaxel and synthesized a series of three docetaxel conjugates. In vitro cytotoxicity of these molecules was evaluated using the MTT assay. Based on the assay results, we selected the conjugate which showed cytotoxic potential close to unmodified docetaxel. At the same time, the molar solubility of the resulting compound increased up to 20 times in comparison with the drug itself. In vivo evaluation on 22Rv1 (PSMA+) xenograft model demonstrated a good potency of the synthesized conjugate to inhibit tumor growth: the inhibition turned out to be more than 80% at a dose of 30 mg/kg. Pharmacokinetic parameters of conjugate distribution were analyzed. Also, it was found that PSMA-targeted docetaxel conjugate is less toxic than docetaxel itself, the decrease of molar acute toxicity in comparison with free docetaxel was up to 20%. Obtained conjugate PSMA-DOC is a good candidate for further expanded preclinical trials because of high antitumor activity, fewer side toxic effects and better solubility. [Display omitted] • A series of three docetaxel PSMA-targeted conjugates were synthesized. • The most potent conjugate PSMA-DOC demonstrated IC 50 value 2.7 on 22Rv1 cell line. • Tumor growth inhibition on 22Rv1 xenografts was 87% at a PSMA-DOC dosage of 10 mg/kg. • PSMA-DOC conjugate demonstrated increased solubility and decreased general toxicity. • PSMA-DOC pharmacokinetics, subchonic and chronic toxicities were estimated. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.